## Abstract The nonstructural 5B (NS5B) protein of hepatitis C virus possesses RNAβdependent RNA polymerase activity and plays an essential role in viral replication. The mutations in NS5B were determined and the correlation with viral load and response to interferon (IFN) were assessed. The entire
Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon
β Scribed by Makoto Kobayashi; Kazumasa Watanabe; Masatoshi Ishigami; Kenichi Murase; Hiroshi Ito; Koji Ukai; Motoyoshi Yano; Kenji Takagi; Masaki Hattori; Shinichi Kakumu; Kentaro Yoshioka
- Book ID
- 119392251
- Publisher
- Nature Publishing Group
- Year
- 2002
- Tongue
- English
- Weight
- 254 KB
- Volume
- 97
- Category
- Article
- ISSN
- 0002-9270
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Patients with low titer (<0.5 mEq/ml) of hepatitis C virus (HCV) genotype 2a achieve high and sustained response (SR) rates to interferon (IFN) monotherapy, but we also encounter patients who are resistant to therapy. We explored the relationship between response to IFN and virological
## An association has been reported between mutations in the amino acid residues 2209-2248 of the nonstructural protein 5A (NS5A) gene (interferon-sensitivity determining region [ISDR]) and interferon efficacy in hepatitis C virus (HCV)-1b infection. This relationship was analyzed in chronic HCV-2
GB virus C (GBV-C) is related to hepatitis C virus (HCV) and has a similar genomic structure. Some predictors for the efficacy of interferon (IFN) therapy on HCV have been reported: genotype, viral load, IFN dose, and the amino acid substitutions in the NS5A region, designated as the interferon sens
of patients with a high likelihood of response to IFN-b. In chronic hepatitis C virus (HCV) infection, geno-(HEPATOLOGY 1997;25:750-753.) types other than genotype 1b of HCV (HCV-1b) and low serum HCV-RNA levels are known to be associated with favorable outcome of interferon alfa (IFN-a) therapy. In